Saturday, 21 June 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 21 June 2025
News

Lilly makes "difficult" decision

Posted 20 June 2025 PM 

Another highly-anticipated medicine pulled? Our readers clicked to find out that Eli Lilly has dropped plans to list Ebglyss on the PBS after struggling to secure a commercially viable price for the eczema drug, making it our top read story of the week. 

For the company, it's a case of deja vu, which halted the launch of its highly anticipated ulcerative colitis treatment Omvoh in January 2024 due to pricing issues. 

To see the whole article, please login

Popular

Five MDs to talk at new event
Who's relocated to the CBD?
Pharma moves into OTC market
Novartis drug to dominate sector
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (9)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (3)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home